{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:51:44Z","timestamp":1791294704166,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/leu.2015.319","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T07:40:55Z","timestamp":1447918855000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling"],"prefix":"10.1038","volume":"30","author":[{"given":"M","family":"Kordes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"R\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Heining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ge\u00f6rg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gr\u00f6schel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Geissinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"von Kalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Brors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gr\u00fcllich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"BFleu2015319_CR1","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124: 3007\u20133015.","journal-title":"Blood"},{"key":"BFleu2015319_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"B Hervier","year":"2014","unstructured":"Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, N\u00e9el et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation. Blood 2014; 124: 1119\u20131126.","journal-title":"Blood"},{"key":"BFleu2015319_CR3","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","volume":"124","author":"JF Emile","year":"2014","unstructured":"Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014; 124: 3016\u20133019.","journal-title":"Blood"},{"key":"BFleu2015319_CR4","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","volume":"123","author":"DS Nelson","year":"2014","unstructured":"Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bov\u00e9e JV et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 2014; 123: 3152\u20133155.","journal-title":"Blood"},{"key":"BFleu2015319_CR5","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/emboj.2012.100","volume":"31","author":"M R\u00f6ring","year":"2012","unstructured":"R\u00f6ring M, Herr R, Fiala GJ, Hellmann K, Braun S, Eisenhardt AE et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012; 31: 2629\u20132647.","journal-title":"EMBO J"},{"key":"BFleu2015319_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855\u2013867.","journal-title":"Cell"},{"key":"BFleu2015319_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nsmb.2924","volume":"22","author":"N Thevakumaran","year":"2014","unstructured":"Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol 2014; 22: 37\u201343.","journal-title":"Nat Struct Mol Biol"},{"key":"BFleu2015319_CR8","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945\u2013D950.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2015319_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949\u2013954.","journal-title":"Nature"},{"key":"BFleu2015319_CR10","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.14694\/EdBook_AM.2014.34.e441","volume":"34","author":"RJ Arceci","year":"2013","unstructured":"Arceci RJ . Biological and therapeutic implications of the BRAF pathway in histiocytic disorders. Am Soc Clin Oncol Educ Book 2013; 34: e441\u2013e445.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"BFleu2015319_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito P, Rosen N, Solit DB . Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19: 1401\u20131409.","journal-title":"Nat Med"},{"key":"BFleu2015319_CR12","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L, von Deimling A, H\u00e9lias-Rodzewicz Z, Hervier B et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120: 2700\u20132703.","journal-title":"Blood"},{"key":"BFleu2015319_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/his.12416","volume":"65","author":"H Go","year":"2014","unstructured":"Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ et al. Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014; 65: 261\u2013272.","journal-title":"Histopathology"},{"key":"BFleu2015319_CR14","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507\u20132516.","journal-title":"N Engl J Med"},{"key":"BFleu2015319_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358\u2013365.","journal-title":"Lancet"},{"key":"BFleu2015319_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche J, Cohen-Aubart F, Emile J-F, Arnaud L, Maksud P, Charlotte F et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121: 1495\u20131500.","journal-title":"Blood"},{"key":"BFleu2015319_CR17","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1200\/JCO.2012.45.9495","volume":"31","author":"S Dietrich","year":"2013","unstructured":"Dietrich S, H\u00fcllein J, Hundemer M, Lehners M, Jethwa A, Capper D et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 2013; 31: e300\u2013e303.","journal-title":"J Clin Oncol"},{"key":"BFleu2015319_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862\u2013869.","journal-title":"Cancer Discov"},{"key":"BFleu2015319_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJMc1215697","volume":"368","author":"MH Rosove","year":"2013","unstructured":"Rosove MH, Peddi PF, Glaspy JA . BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013; 368: 684\u2013685.","journal-title":"N Engl J Med"},{"key":"BFleu2015319_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431\u2013435.","journal-title":"Nature"},{"key":"BFleu2015319_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209\u2013221.","journal-title":"Cell"},{"key":"BFleu2015319_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N . RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427\u2013430.","journal-title":"Nature"},{"key":"BFleu2015319_CR23","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/JCI76539","volume":"124","author":"N Yaktapour","year":"2014","unstructured":"Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest 2014; 124: 5074\u20135084.","journal-title":"J Clin Invest"},{"key":"BFleu2015319_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","volume":"23","author":"R Halaban","year":"2010","unstructured":"Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010; 23: 190\u2013200.","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFleu2015319_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature11284","volume":"488","author":"DT Jones","year":"2012","unstructured":"Jones DT, J\u00e4ger N, Kool M, Zichner T, Hutter B, Sultan M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100\u2013105.","journal-title":"Nature"},{"key":"BFleu2015319_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"D Capper","year":"2011","unstructured":"Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11\u201319.","journal-title":"Acta Neuropathol"},{"key":"BFleu2015319_CR27","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1097\/JTO.0b013e3181f0beca","volume":"5","author":"SYS Lee","year":"2010","unstructured":"Lee SYS, Kim MJM, Jin GG, Yoo SS, Park JY, Choi JE et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5: 1734\u20131740.","journal-title":"J Thorac Oncol"},{"key":"BFleu2015319_CR28","first-page":"4878","volume":"63","author":"TL Chan","year":"2003","unstructured":"Chan TL, Zhao W, Leung SY, Yuen ST, Yuen ST . BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003; 63: 4878\u20134881.","journal-title":"Cancer Res"},{"key":"BFleu2015319_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/gut.52.5.706","volume":"52","author":"A Tannapfel","year":"2003","unstructured":"Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706\u2013712.","journal-title":"Gut"},{"key":"BFleu2015319_CR30","first-page":"6451","volume":"62","author":"ST Yuen","year":"2002","unstructured":"Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451\u20136455.","journal-title":"Cancer Res"},{"key":"BFleu2015319_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/ng.2798","volume":"45","author":"G Guo","year":"2013","unstructured":"Guo G, Sun X, Chen C, Wu S, Huang P, Li Z et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45: 1459\u20131463.","journal-title":"Nat Genet"},{"key":"BFleu2015319_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011; 17: 229\u2013235.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015319_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1158\/1078-0432.CCR-11-2056","volume":"18","author":"N Shukla","year":"2012","unstructured":"Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012; 18: 748\u2013757.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015319_CR34","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1126\/science.1124642","volume":"311","author":"P Rodriguez-Viciana","year":"2006","unstructured":"Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311: 1287\u20131290.","journal-title":"Science"},{"key":"BFleu2015319_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng1641","volume":"37","author":"Y Aoki","year":"2005","unstructured":"Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37: 1038\u20131040.","journal-title":"Nat Genet"},{"key":"BFleu2015319_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124: 483\u2013492.","journal-title":"Blood"},{"key":"BFleu2015319_CR37","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.5858\/2005-129-e39-FMNCHP","volume":"129","author":"RN Rao","year":"2005","unstructured":"Rao RN, Chang C-C, Uysal N, Presberg K, Shidham VB, Thomashefski JF . Fulminant multisystem non-langerhans cell histiocytic proliferation with hemophagocytosis: a variant form of Erdheim-Chester disease. Arch Pathol Lab Med 2005; 129: e39\u2013e43.","journal-title":"Arch Pathol Lab Med"},{"key":"BFleu2015319_CR38","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1200\/JCO.2007.10.8613","volume":"25","author":"JA Gollob","year":"2007","unstructured":"Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288\u20133295.","journal-title":"J Clin Oncol"},{"key":"BFleu2015319_CR39","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1128\/MCB.00057-14","volume":"34","author":"AS Shaw","year":"2014","unstructured":"Shaw AS, Kornev AP, Hu J, Ahuja LG, Taylor SS . Kinases and pseudokinases: lessons from RAF. Mol Cell Biol 2014; 34: 1538\u20131546.","journal-title":"Mol Cell Biol"},{"key":"BFleu2015319_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387\u2013390.","journal-title":"Nature"},{"key":"BFleu2015319_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.molcel.2012.12.018","volume":"49","author":"AK Freeman","year":"2013","unstructured":"Freeman AK, Ritt DA, Morrison DK . Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 2013; 49: 751\u2013758.","journal-title":"Mol Cell"},{"key":"BFleu2015319_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2013.06.014","volume":"82","author":"H Sasaki","year":"2013","unstructured":"Sasaki H, Shimizu S, Tani Y, Shitara M, Okuda K, Hikosaka Y et al. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer 2013; 82: 51\u201354.","journal-title":"Lung Cancer"},{"key":"BFleu2015319_CR43","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1200\/JCO.2012.46.1061","volume":"31","author":"P Bahadoran","year":"2013","unstructured":"Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D et al. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol 2013; 31: e324\u2013e326.","journal-title":"J Clin Oncol"},{"key":"BFleu2015319_CR44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","volume":"2","author":"KB Dahlman","year":"2012","unstructured":"Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012; 2: 791\u2013797.","journal-title":"Cancer Discov"},{"key":"BFleu2015319_CR45","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.1257","volume":"9","author":"H Lavoie","year":"2013","unstructured":"Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 2013; 9: 428\u2013436.","journal-title":"Nat Chem Biol"},{"key":"BFleu2015319_CR46","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893\u20131901.","journal-title":"Lancet"},{"key":"BFleu2015319_CR47","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/leu.2011.2","volume":"25","author":"S Huber","year":"2011","unstructured":"Huber S, Oelsner M, Decker T, zum B\u00fcschenfelde CM, Wagner M, Lutzny G et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25: 838\u2013847.","journal-title":"Leukemia"},{"key":"BFleu2015319_CR48","first-page":"8132","volume":"63","author":"T Ikenoue","year":"2003","unstructured":"Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003; 63: 8132\u20138137.","journal-title":"Cancer Res"},{"key":"BFleu2015319_CR49","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1101\/gad.193458.112","volume":"26","author":"C Andreadi","year":"2012","unstructured":"Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K et al. The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF\/MEK\/ERK pathway. Genes Dev 2012; 26: 1945\u20131958.","journal-title":"Genes Dev"},{"key":"BFleu2015319_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","volume":"27","author":"MR Girotti","year":"2015","unstructured":"Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 2015; 27: 85\u201396.","journal-title":"Cancer Cell"},{"key":"BFleu2015319_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358\u2013367.","journal-title":"Cancer Discov"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015319","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:13:34Z","timestamp":1648743214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFleu2015319"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.319","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"assertion":[{"value":"17 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}